$45
$62.55
Core Subject: This medical resource covers essential aspects of Scripps 39th Annual, designed for high-yield board review and clinical excellence.Scripps 39th Annual New Treatments in Chronic Liver Disease 202539th Annual New Treatments in Chronic Liver Disease�� March 15–16, 2025 · Coronado Island Marriott · Coronado, CaliforniaHepatology GI Updates CME-OrientedOne-time access · Lifetime availability · Google Drive deliveryConference OverviewThis conference reviews the latest medications and therapies in liver disease treatment and transplantation, featuring trial results and real-world data for chronic viral hepatitis B/C, metabolic liver disease (NAFLD/MASH), cholestatic disease (PBC/PSC), hepatocellular carcinoma (HCC), and end-stage liver disease (ESLD) complications including thrombocytopenia. Designed as a comprehensive yet concise update, it helps clinicians integrate evidence-based strategies into daily practice.Educational ObjectivesCite new strategies for identifying and managing metabolic liver disease.Review updated goals and guidelines for Delta hepatitis, HBV and HCV.Discuss potential new treatments for alcohol-related liver disease.Summarize novel markers and therapies in PBC and PSC.Evaluate liver masses and new therapeutic options for HCC.Employ strategies for treating and managing ascites and hepatorenal syndrome.Who Should AttendHepatologists and gastroenterologists managing cirrhosis, hepatitis, NAFLD/MASH, and chronic liver conditionsTransplant hepatologists and surgeons involved in liver transplantation and advanced liver failure careInternists and primary care physicians needing practical liver-disease updatesResidents, fellows, and trainees preparing for hepatology / GI practice or board examsNurses, nurse practitioners, and physician assistants in hepatology, GI, or transplant programsWhat You’ll LearnUpdated pharmacologic therapies for HBV/HCV, MASH/NAFLD, alcohol-related liver disease, and cholestatic disordersNon-invasive fibrosis assessment, imaging approaches, and evolving biomarkersManagement of cirrhosis and portal hypertension complications (ascites, variceal bleeding, encephalopathy)HCC evaluation pathways and systemic therapy updatesTransplant selection strategies, outcomes, and emerging clinical trial directionsScientific Program HighlightsTwo-day agenda featuring metabolic liver disease risk stratification, lifestyle prescriptions, incretin-based strategies for MASH T2D, MASH drug development, HBV CAMs, updated hepatitis B/C guidance, cholestatic disease/pruritus, alcohol hepatitis, refractory hepatic encephalopathy, mock HCC tumor board, systemic therapies for HCC, and emerging HBV ASO/siRNA therapeutics.Agenda, faculty, and schedule are subject to change.Bundle & Save: Enjoy 15% OFF when purchasing two or more related GI/hepatology courses. This offer is permanent and unlimited.Related Gastroenterology & Hepatology CoursesCourseBest ForRatingThe Pass Machine Gastroenterology QBank (Windows & Android)Board-style practice rapid review★★★★★Prometric Gastroenterology QBank 2025 (Windows & Android)Certification prep targeted drilling★★★★★BoardVitals Gastroenterology QBank 2025High-yield QBank self-assessment★★★★★Mayo Clinic Gastroenterology & Hepatology Board Review 2024Comprehensive board-focused review★★★★★2025 William M. Steinberg Board Review in Gastroenterology – Best PracticesGuideline-driven GI mastery★★★★☆Harvard Gastroenterology 2025Clinical updates evidence integration★★★★★FAQHow is access provided?All materials are delivered via Google Drive with lifetime, unlimited access.Is this useful for hepatology and transplant-focused practice?Yes. The agenda includes advanced management of ESLD complications, HCC strategies, and transplant-relevant updates.Does it cover modern metabolic liver disease therapies?Yes. Topics include MASH risk stratification, lifestyle prescriptions, incretin-based approaches, and MASH drug development.
Gastroenterology
